TY - JOUR
T1 - The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review
AU - Cheah, Chan Yoon
AU - Hofman, Michael S
AU - Seymour, John Francis
AU - Ritchie, David S
AU - Dickinson, Michael J
AU - Wirth, Andrew
AU - Prince, Henry Miles
AU - Wolf, Max
AU - Januszewicz, Elchanan Henry
AU - Carney, Dennis A
AU - Herbert, Kirsten E
AU - Harrison, Simon James
AU - Burbury, Kate L
AU - Tam, Constantine S
PY - 2015
Y1 - 2015
N2 - There are limited data regarding the role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT) scanning in primary mediastinal B-cell lymphoma (PMBL). We analyzed 28 patients with PMBL treated with chemotherapy, of whom 25 (89 ) also received rituximab and 17 (61 ) radiotherapy. PET-CT scans were interpreted using visual analysis and a 5-point scale. After a median follow-up of 2.6 years, four patients relapsed and two died. The 2-year progression-free survival and overall survival were 86 and 94 . PET-CT has excellent negative predictive value (interim, 86-87 ; end of treatment, 95 ) but limited positive predictive value due to the high frequency of positive scans. Several patients with persistent metabolically active masses underwent biopsies, which showed necrosis but no lymphoma. Thus a negative PET-CT is an excellent predictor of subsequent outcome. However, residual metabolically active masses after treatment should be biopsied to confirm viable lymphoma prior to salvage therapy.
AB - There are limited data regarding the role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT) scanning in primary mediastinal B-cell lymphoma (PMBL). We analyzed 28 patients with PMBL treated with chemotherapy, of whom 25 (89 ) also received rituximab and 17 (61 ) radiotherapy. PET-CT scans were interpreted using visual analysis and a 5-point scale. After a median follow-up of 2.6 years, four patients relapsed and two died. The 2-year progression-free survival and overall survival were 86 and 94 . PET-CT has excellent negative predictive value (interim, 86-87 ; end of treatment, 95 ) but limited positive predictive value due to the high frequency of positive scans. Several patients with persistent metabolically active masses underwent biopsies, which showed necrosis but no lymphoma. Thus a negative PET-CT is an excellent predictor of subsequent outcome. However, residual metabolically active masses after treatment should be biopsied to confirm viable lymphoma prior to salvage therapy.
UR - http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.910656
U2 - 10.3109/10428194.2014.910656
DO - 10.3109/10428194.2014.910656
M3 - Article
SN - 1042-8194
VL - 56
SP - 49
EP - 56
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -